Time Medical International Ventures (India) Private Limited ("Time Medical India"), a wholly owned subsidiary of Fischer Medical Ventures Limited , has entered into a partnership with Parul Sevashram Hospital in Vadodara to install its DRIS-iMRI Medharanya Suite. Announced on July 31, 2026, the collaboration marks the deployment of an AI-enabled, next-generation portable intraoperative MRI system designed to enhance precision and safety in complex neurosurgical procedures through real-time visualization.

The partnership aligns with Parul Sevashram Hospital's vision of "Health for All" and its commitment to accessible, high-quality healthcare. As the teaching hospital of Parul Institute of Medical Sciences & Research, a constituent institute of Parul University, the facility serves a student community of over 43,000, including more than 2,500 international students from over 68 countries. Parul University is noted as one of India's largest multidisciplinary private universities and the youngest to receive NAAC A++ accreditation in its first assessment cycle.

Technology Overview

The DRIS-iMRI Medharanya Suite represents a new variant of MRI imaging technology developed by Time Medical India. The system integrates multiple advanced technologies into a single intelligent surgical ecosystem:

This integrated platform unifies diagnostic and surgical workflows, enabling faster decision-making and unparalleled visualization of complex neurological anatomy beyond conventional imaging methods.

Clinical and Academic Impact

Svetlana Rao, Director at Time Medical India, stated that the upcoming partnership will mark a landmark deployment of a next-generation intraoperative MRI Brain Suite in India. She noted that the collaboration is expected to enhance neurosurgical precision, improve clinical outcomes, and strengthen advanced neurocare capabilities at the hospital.

Beyond clinical applications, the installation is expected to strengthen the academic and clinical ecosystem at Parul University. The suite will provide medical students, residents, and faculty with hands-on exposure to next-generation neurosurgical imaging technology, supporting education across Medicine, Engineering, Pharmacy, Ayurveda, Homoeopathy, Management, Law, and Design faculties.

Development Collaboration

The DRIS-iMRI Medharanya platform is being jointly developed by Time Medical India in collaboration with Dr. Iype Cherian, a globally renowned neurosurgeon, educator, and innovator. Dr. Cherian completed his M.Ch (Neurosurgery) at CMC Vellore and advanced fellowship training in Skull Base and Vascular Neurosurgery at Nagoya, Japan. He is internationally recognized for pioneering neurosurgical techniques, including novel craniotomy approaches and the concept of Brain Cooling.

Time Medical India worked closely with surgeons to understand real-world requirements in building the solution. Headquartered in Chennai, Time Medical India specializes in the design and manufacture of high-performance, cost-effective MRI systems aimed at democratizing access to advanced diagnostic imaging across emerging and developed markets.

Fischer Medical Ventures Limited announced on July 30, 2026, that its associate company, Nanomedic Technologies Ltd., has secured import approval from the Central Drugs Standard Control Organisation (CDSCO) for the Spincare Portable Wound Care System. The regulatory clearance, issued under Form MD-27 of the Medical Devices Rules, 2017, permits the import and distribution of the Class C medical device in India. This approval marks a significant milestone as it represents India's first regulatory clearance for a portable electrospun wound care system, positioning the company to capture market share in the advanced wound care sector.

The Spincare system is a handheld device that applies a breathable, transparent nano-fiber film directly onto wounds at the point of care, eliminating the need for traditional dressings in many clinical scenarios. The device is indicated for use across various skin breaches, including partial and full thickness wounds, burns, donor site wounds, surgical incisions, and chronic ulcers. Designed for use by healthcare professionals in clinical environments, the system carries a five-year shelf life. Nanomedic Technologies Ltd., headquartered in Lod, Israel, manufactures the system using proprietary electrospinning technology to create a nano-fiber protective layer that accelerates healing and reduces infection risk.

Fischer Medical Ventures holds exclusive rights to distribute the Spincare system across India and Southeast Asia. The Indian wound care market is valued at approximately USD 380 million in 2026 and is projected to reach USD 1.8 billion by 2033, growing at a compound annual growth rate (CAGR) of approximately 6.4%, according to IMARC Group. Key demand drivers include rising diabetes prevalence, increasing surgical volumes, and the growth of home healthcare. In Southeast Asia, the advanced wound care segment is projected to reach USD 354 million by 2030, with a CAGR of approximately 6.1%, driven by increasing awareness of wound management and a rising burden of chronic diseases in countries such as Indonesia, Malaysia, and Singapore.

Market Opportunity and Regional Growth

The following table outlines the projected market values for the regions where Fischer Medical Ventures holds exclusive distribution rights:

Ravindran Govindan, Chairman and Managing Director of Fischer Medical Ventures Limited, stated that receiving CDSCO clearance is a transformative moment for the company. He noted that the approval opens the door to deploying differentiated wound care technology across Indian hospitals and burn centers, highlighting substantial whitespace in the market.

Regulatory Status and Future Approvals

While the CDSCO approval enables immediate commercialization in India, Nanomedic Technologies Ltd. has submitted an application for U.S. Food and Drug Administration (FDA) approval for the Spincare system. The approval process is currently underway, with the company expecting FDA clearance soon. This potential milestone would further validate the product's safety and efficacy standards and strengthen the group's standing in global markets. The Spincare system has already received regulatory approvals in multiple jurisdictions globally.

What the Numbers Show

The strategic value of this approval lies in the convergence of exclusive distribution rights and high-growth market projections. With the Indian market expected to nearly quintuple from USD 380 million to USD 1.8 billion over seven years, Fischer Medical Ventures is entering the sector at the beginning of a significant expansion cycle. The exclusive nature of the partnership in both India and Southeast Asia provides a protected revenue stream in two of the fastest-growing healthcare markets, mitigating competitive risk during the initial commercialization phase.